Program
ritlecitinib
Also written as “PF-06651600”, “Ritlecitinib” and “Ritlecitinib 50 mg”.
Its studies are mostly in Alopecia Areata · Vitiligo · Arthritis, Rheumatoid · Hidradenitis Suppurativa · Chronic Urticaria, led by Pfizer.
Furthest: phase 3, since Nov 5, 201842 company-led studies, 8 open or runningNext primary completion: Dec 2, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 428 open or running | phase 3since Nov 5, 2018 | Feb 12, 2016 | Dec 2, 2026phase 3 · NCT07029711 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Feb 12, 2016.
- Nov 2, 2020Phase 1 study in Healthy ParticipantsNCT04634565 · 9 enrolled · China
- Sep 2, 2021Phase 1 study in Healthy ParticipantsNCT05040295 · 12 enrolled · United States
- Oct 14, 20212 phase 1 studiesNCT05097716, NCT05128058
- Oct 6, 2022Phase 3 study in Stable Nonsegmental VitiligoNCT05583526 · 607 enrolled · United States, Australia, Bulgaria and more
- Dec 6, 2022Phase 1 study in Alopecia AreataNCT05650333 · 15 enrolled · United States
- May 1, 2023Phase 1 study in Healthy VolunteersNCT05852340 · 12 enrolled · Belgium
- Oct 2, 2023Phase 3 study in Stable Nonsegmental VitiligoNCT06072183 · 1,571 enrolled · United States, Australia, Belgium and more
- Nov 30, 2023Phase 3 study in VitiligoNCT06163326 · 394 enrolled · United States, Australia, Bulgaria and more
- Dec 7, 2023Phase 1 study in Healthy VolunteersNCT06172348 · 12 enrolled · Belgium
- Apr 11, 2024Phase 1 study in Healthy VolunteersNCT06369454 · 12 enrolled · United States
- Mar 7, 2025Phase 3 study in Alopecia AreataNCT06873945 · 674 planned · United States, Canada, China and more
- Jun 11, 20252 phase 3 studies in Alopecia AreataNCT07029828, NCT07029711
- Oct 20, 20252 phase 2 studiesNCT07219615, NCT07228390
- Jul 24, 2026Phase 3 study in Alopecia AreataNCT07733765 · 336 planned · United States, Canada, China and more
Ahead
- Dec 2, 2026Primary completion: phase 3 study in Alopecia AreataNCT07029711
- Dec 8, 2026Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07228390
- Dec 25, 2026Primary completion: phase 2 study in Chronic UrticariaNCT07219615
- Mar 31, 2027Primary completion: phase 3 study in VitiligoNCT06163326
TargetBeta
“An orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) ”NCIt, by rule
“Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor; Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor”ChEMBL 37, by rule
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07733765Alopecia Areata · United States, Canada, China and more | 3 | Recruiting | Apr 26, 2028 | 336 |
| NCT07228390Hidradenitis Suppurativa · United States, Canada, Germany and more | 2 | Active, not recruiting | Dec 8, 2026 | 128 |
| NCT07219615Chronic Urticaria · United States, Bulgaria, Canada and more | 2 | Recruiting | Dec 25, 2026 | 200 |
| NCT07029828Alopecia Areata · United States, China, Czechia and more | 3 | Recruiting | Jun 26, 2030 | 140 |
| NCT07029711Alopecia Areata · United States, China, Czechia and more | 3 | Active, not recruiting | Dec 2, 2026 | 208 |
| NCT06873945Alopecia Areata · United States, Canada, China and more | 3 | Recruiting | Mar 19, 2028 | 674 |
| NCT06369454Healthy Volunteers · United States | 1 | Completed | Jul 31, 2024 | 12 |
| NCT06172348Healthy Volunteers · Belgium | 1 | Completed | Mar 28, 2024 | 12 |
| NCT06163326Vitiligo · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | Mar 31, 2027 | 394 |
| NCT06072183Stable Nonsegmental Vitiligo · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jul 30, 2027 | 1,571 |
| NCT05852340Healthy Volunteers · Belgium | 1 | Completed | Jun 15, 2023 | 12 |
| NCT05650333Alopecia Areata · United States | 1 | Completed | Aug 11, 2023 | 15 |
| NCT05583526Stable Nonsegmental Vitiligo · United States, Australia, Bulgaria and more | 3 | Completed | Feb 5, 2026 | 607 |
| NCT05128058Healthy · United States | 1 | Completed | Jan 14, 2022 | 16 |
| NCT05097716Healthy Volunteers · United States | 1 | Completed | Jan 10, 2022 | 12 |
| NCT05040295Healthy Participants · United States | 1 | Completed | Nov 19, 2021 | 12 |
| NCT04634565Healthy Participants · China | 1 | Completed | Nov 19, 2020 | 9 |
| NCT04517864Alopecia Areata · United States, Australia, Canada and more | 2 | Terminated | Jan 4, 2022 | 71 |
| NCT04413617Arthritis, Rheumatoid · Bulgaria, Canada, Chile and more | 2 | Completed | Feb 7, 2022 | 460 |
| NCT04390776Healthy Participants · United States | 1 | Completed | Jul 19, 2021 | 164 |
| NCT04355845Healthy Volunteers · United States | 1 | Completed | Aug 10, 2020 | 10 |
| NCT04266509Healthy Volunteers · Belgium | 1 | Completed | Sep 10, 2020 | 12 |
| NCT04092595Healthy Volunteers · Belgium | 1 | Completed | Jan 15, 2020 | 12 |
| NCT04037865Renal Insufficiency · United States | 1 | Terminated | Mar 31, 2020 | 8 |
| NCT04018274Healthy · United States | 1 | Completed | Oct 16, 2019 | 29 |
| NCT04016077Hepatic Impairment · United States | 1 | Completed | Mar 5, 2020 | 18 |
| NCT04006457Alopecia Areata · United States, Argentina, Australia and more | 3 | Completed | Jun 25, 2024 | 1,057 |
| NCT04004663Healthy Volunteers · Belgium | 1 | Completed | Oct 11, 2019 | 12 |
| NCT03929510Healthy Volunteers · Netherlands | 1 | Completed | Jul 5, 2019 | 6 |
| NCT03916393Healthy Participants · Belgium | 1 | Completed | May 10, 2019 | 10 |
| NCT03827668Healthy · United States | 1 | Completed | Apr 29, 2019 | 15 |
| NCT03821493Healthy Participants · Belgium | 1 | Completed | Apr 6, 2019 | 12 |
| NCT03762928Healthy Subjects · United States | 1 | Completed | Jan 27, 2019 | 12 |
| NCT03732807Alopecia Areata · United States, Argentina, Australia and more | 3 | Completed | Dec 31, 2020 | 718 |
| NCT03715829Active Non-segmental Vitiligo · United States, Australia, Belgium and more | 2 | Completed | Feb 5, 2021 | 366 |
| NCT03608241Healthy Females · United States | 1 | Completed | Nov 23, 2018 | 12 |
| NCT03395184Crohn Disease · United States, Australia, Austria and more | 2 | Completed | Oct 19, 2023 | 244 |
| NCT03232905Healthy · Belgium | 1 | Completed | Oct 27, 2017 | 6 |
| NCT02974868Alopecia Areata · United States, Australia, Canada | 2 | Completed | May 15, 2019 | 142 |
| NCT02969044Arthritis, Rheumatoid · United States, Bulgaria, Czechia and more | 2 | Completed | Dec 12, 2017 | 70 |
| NCT02958865Colitis, Ulcerative · United States, Austria, Bulgaria and more | 2 | Completed | May 10, 2021 | 319 |
| NCT02684760Inflammatory Bowel Diseases · Belgium | 1 | Completed | May 2016 | 14 |
How it is read
Names in the registry
- “PF-06651600”, 25 entries
- “Ritlecitinib”, 9 entries
- “Ritlecitinib 50 mg”, 4 entries
- “Ritlecitinib 100 mg”, 4 entries
- “ritlecitinib”, 3 entries
Conditions, from the studies’ own filings
- Alopecia Areata, 9 studies
- Vitiligo, 4 studies
- Arthritis, Rheumatoid, 2 studies
- Hidradenitis Suppurativa, 1 study
- Chronic Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.